NBE-002 in Patients With Advanced Solid Tumors

  • STATUS
    Recruiting
  • participants needed
    100
  • sponsor
    NBE-Therapeutics AG
Updated on 19 February 2024
cancer
breast cancer
serum pregnancy test
measurable disease
solid tumour
solid tumor
sarcoma
progressive disease
carcinoma
triple-negative breast cancer
anthracyclines
systemic therapy
advanced solid tumor
solid neoplasm
advanced malignant solid tumor
anthracycline
blood coagulation tests

Summary

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

Details
Condition Breast Cancer, Breast Cancer, Breast Cancer - HER2 Positive, Advanced Solid Tumor, Advanced Cancer, Chronic Shoulder Pain
Age 18years - 100years
Treatment NBE-002
Clinical Study IdentifierNCT04441099
SponsorNBE-Therapeutics AG
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent
Age 18 years
Phase 1, DEC and SEC: patients with histologically or cytologically confirmed advanced solid tumor (carcinoma or sarcoma), who have progressive disease, have undergone systemic therapy for advanced disease, and for whom no standard therapy is available
Phase 2, EC1: patients with histologically or cytologically confirmed advanced triple-negative breast cancer, who have progressive disease, and have undergone no more than three prior lines of systemic therapy for advanced disease
Phase 2, EC2: patients with histologically or cytologically confirmed advanced solid tumor (carcinoma or sarcoma) other than TNBC, who have progressive disease, and have undergone no more than three prior lines of systemic therapy for advanced disease
Availability of pretreatment tumor tissue
Phase 1, DEC and SEC: at least one measurable or non-measurable lesion as per RECIST v1.1
Phase 2, EC1 and EC2: at least one measurable lesion as per RECIST v1.1
Phase 1, DEC and SEC: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Phase 2, EC1 and EC2: ECOG performance status of 0 or 1
Adequate function of bone marrow, liver, kidneys, heart; adequate coagulation profile
Both male and female patients must agree to use effective contraceptive methods
Women of child-bearing potential (WCBP) must have a negative serum pregnancy test
Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

Prior treatment with any agent targeting ROR1
Presence of active central nervous system (CNS) metastasis
Persistent toxicities from previous systemic anti-neoplastic treatments of Grade > 1 (or Grade > 2 for neurotoxicity)
Systemic anti-neoplastic therapy within five half-lives or four weeks (six weeks for nitrosourea and mitomycin-C), whichever is shorter, prior to first dose of the study drug
Wide-field radiotherapy within four weeks, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within two weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
Major surgery within four weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
Prior allogeneic bone marrow transplantation
Significant cardiac disease
History of thromboembolic or cerebrovascular events within six months prior to first dose of the study drug
Acute and/or clinically significant bacterial, fungal or viral infection
Concomitant use of systemic steroids at dose of >10 mg of prednisone or its equivalent per day
Concurrent participation in another investigational clinical trial
Pregnant or breast-feeding females
Other conditions that prevent the patient from giving informed consent or participating in the trial, or that may increase the risk associated with the study participation, or that may interfere with the interpretation of the study results
Prior history of malignancy other than inclusion diagnosis within three years prior to first dose of the study drug
Prior treatment with cumulative lifetime dose of anthracycline
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.